socalTECH

MARCH 8, 2016

Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Lightstone Ventures also participated in the funding. Tizona is based in South San Francisco, and is developing treatments for cancer and autoimmune diseases.

Thousand Oaks 100

Thousand Oaks Funding Venture Capital Invest 100

socalTECH

OCTOBER 31, 2017

Thousand Oaks-based biotech giant a href="[link] said on Monday that it has agreed to acquire its joint venture with Kirin, Kirin-Amgen , in a deal worth $780M. The JV was created in 1984 as a 50-50 joint venture to fund global development of Amgen's EPOGEN, and later included the company's other pharmaceutical products.

Thousand Oaks 113

Thousand Oaks Startup Funding Help 113

socalTECH

APRIL 20, 2017

Thousand Oaks-based wireless networking equipment maker Xirrus has been acquired by Riverbed , to help bolster its SD WAN efforts, the two said on Wednesday. Riverbed said it will continue to offer up Xirrus as a stand-alone enterprise WLAN solution. Financial terms of the acquisition were not announced. READ MORE>>.

Thousand Oaks 127

Thousand Oaks Acquisition Startup Networking 127

SoCal Tech Calendar

DECEMBER 3, 2018

Wednesday, December 5, 2018 -- Startups: The Year That Was and The Year That's Ahead. He will talk about some of the noteworthy funding deals, acquisitions, exits and trends of 2018, and talk about what might be in store for the future. Cal Lutheran Center for Entrepreneurship. Wednesday, December 5, 6 - 8 p.m., See [link] (more)

Thousand Oaks 100

Thousand Oaks Startup Acquisition Funding 100

socalTECH

OCTOBER 9, 2015

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. Adheron said that it has been acquired by Roche , in a deal worth $105M upfront and up to $475M in additional milestone payments.

Thousand Oaks 100

Thousand Oaks Venture Capital Activity Capital 100

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M As part of the funding, F-Prime's Thomas Beck and Ben Auspitz have joined the company's board. in a Series A investment. The investment came from F-Prime Capital Partners.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

OCTOBER 29, 2015

in a funding round. Brett and I both grew up in Southern California. I grew up in Thousand Oaks, went to USC, and we met each other way back in the 90's. How did you guys start the company? I came up with this idea due to a deep obsession with the mortgage industry. So, what is PeerStreet?

Southern California 145

Southern California Google Technical Review Manhattan Beach 145

Xconomy

JULY 22, 2016

But there’s plenty more to dig through as well, from a shakeup at Zafgen to a few new high profile startups and a newly public gene therapy company. It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment.

Startup 40

Startup San Diego News Thousand Oaks 40

socalTECH

APRIL 29, 2014

We caught up with one of the local teams competing in that competition, VOXearch (www.voxearch.com), to learn more about the prize as well as their specific approach to the competition. Mike Outmesguine: We''re one of about thirty teams left in the challenge, out of more than 300 that signed up last August.

Startup 262

Startup Competition Software Review UCLA 262

socalTECH

JANUARY 27, 2020

The crash site where Bryant and the others crashed is within view of a cluster of business parks, which houses some of the high tech companies along the 101 corridor.

Thousand Oaks 113

Thousand Oaks Legalzoom Calabasas High Tech 113

Xconomy

JUNE 10, 2016

Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. As the conference wrapped up, a Morgan Stanley analyst noted that Pfizer the previous week had raised its drug prices nine percent, continuing a regular pattern of price increases.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. —Pfizer wasn’t done after scooping up Medivation.

Pricing 45

Pricing Thousand Oaks Startup Research 45